FTC weighs in on reverse-payment generic delay case involving Gilead, Teva [Seeking Alpha]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Seeking Alpha
Sciences ( NASDAQ: GILD ) that paid Teva Pharmaceutical Industries ( NYSE: TEVA ) to delay generic versions of the former's HIV meds, Truvada and Atripla. At the heart of the case is the idea of "reverse-payment agreements," in which a party, usually a generic drug maker, agrees to drop a patent lawsuit against a brand name company in exchange for a payment. As a result, generic version of a drug are delayed coming to market. In 2023, a California jury found in favor of Gilead and Teva. The two pharmas entered into patent settlement in 2014. Generic drug companies routinely file Abbreviated New Drug Applications after a brand drug is approved. Some of those generic drugmakers seek to market their drug before key patents on the brand version through a "Paragraph IV" certification that challenges a patent's validity or argues the generic version will not infringe a patent. That certification usually prompts the brand company to file a patent infringement suit against the generic c
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Epinephrine Autoinjectors Industry Research Business Report 2024 Featuring ALK-Abello, Bausch + Lomb, Emerade, Teva Pharmaceutical [Yahoo! Finance]Yahoo! Finance
- Blue Wolf Capital to Create New CDMO Platform [Yahoo! Finance]Yahoo! Finance
- Teva Pharmaceutical Industries Limited (NYSE: TEVA) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive DyskinesiaGlobeNewswire
TEVA
Earnings
- 7/31/24 - Beat
TEVA
Sec Filings
- 9/4/24 - Form 4
- 8/14/24 - Form 144/A
- 8/14/24 - Form 144/A
- TEVA's page on the SEC website